INSULIN-LIKE GROWTH FACTOR I REDUCES CORONARY ATHEROSCLEROSIS IN PIGS WITH FAMILIAL HYPERCHOLESTEROLEMIA
Author:
Sukhanov SergiyORCID, Higashi Yusuke, Yoshida Tadashi, Danchuk Svitlana, Alfortish Mitzi, Goodchild Traci, Scarborough Amy, Sharp Thomas, Jenkins James S., Garcia Daniel, Ivey Jan, Tharp Darla L., Schumacher Jeffrey, Rozenbaum Zach, Kolls Jay K., Bowles Douglas, Lefer David, Delafontaine Patrice
Abstract
ABSTRACTObjectiveAlthough murine models of coronary atherosclerotic disease (CAD) have been used extensively to determine mechanisms, limited new therapeutic options have emerged. Pigs with familial hypercholesterolemia (FH pigs) develop complex coronary atheromas that are almost identical to human lesions. We reported previously that insulin-like growth factor 1 (IGF-1) reduced aortic atherosclerosis and promoted features of stable plaque in a murine model. We tested IGF-1 effects in atherosclerotic FH pigs to consider use of IGF-1 to treat CAD in humans. FH pigs were administered with IGF-1 for 6 months. Atherosclerosis was quantified by serial intravascular ultrasound (IVUS) and histology, plaque composition - by immunohistochemistry. We used spatial transcriptomics (ST) analysis to identify global transcriptome changes in advanced plaque compartments and to obtain mechanistic insights into IGF-1 effects.ResultsIGF-1-injected FH pigs had 1.8-fold increase in total circulating IGF-1 levels compared to control. IGF-1 decreased relative coronary atheroma (IVUS) and lesion cross-sectional area (histology). IGF-1 induced vascular hypertrophy and reduced circulating triglycerides, markers of systemic oxidative stress and pro-atherogenic CXCL12 chemokine levels. IGF-1 increased fibrous cap thickness, and reduced necrotic core size, macrophage content, and cell apoptosis, changes consistent with promotion of a stable plaque phenotype. IGF-1 suppressed FOS/FOSB factors and gene expression of MMP9 and CXCL14 in plaque macrophages, suggesting possible involvement of these molecules in IGF-1’s effect on atherosclerosis.ConclusionsIGF-1 reduced coronary plaque burden and promoted features of stable plaque in a pig model, providing support for consideration of clinical trials. ST profiling of plaques provided novel insights into potential mechanisms.
Publisher
Cold Spring Harbor Laboratory
Reference71 articles.
1. Executive Summary: Heart Disease and Stroke Statistics—2016 Update 2. Tsao CW , Aday AW , Almarzooq ZI , Alonso A , Beaton AZ , Bittencourt MS , Boehme AK , Buxton AE , Carson AP , Commodore-Mensah Y , Elkind MSV , Evenson KR , Eze-Nliam C , Ferguson JF , Generoso G , Ho JE , Kalani R , Khan SS , Kissela BM , Knutson KL , Levine DA , Lewis TT , Liu J , Loop MS , Ma J , Mussolino ME , Navaneethan SD , Perak AM , Poudel R , Rezk-Hanna M , Roth GA , Schroeder EB , Shah SH , Thacker EL , VanWagner LB , Virani SS , Voecks JH , Wang NY , Yaffe K , Martin SS , American Heart Association Council on E, Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022:CIR0000000000001052. 3. Coronary Atheroma Burden Is the Main Determinant of Patient Outcome 4. Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species;Sci Rep,2018 5. The representative porcine model for human cardiovascular disease;J Biomed Biotechnol,2011
|
|